| abstract |
In various embodiments, methods for treating the emotional or psychological symptoms of Fragile X Syndrome (FXS) in human patients by administering an effective dose of a compound that is an inhibitor of the synthetic enzyme cortisol 11β-hydroxysteroid dehydrogenase type 1 (HSD11β1), or an effective dose of a corticotropin-releasing hormone (CRH) receptor antagonist. For example, an effective dose of one of these two classes of drugs is administered to a patient for treatment when the emotional and psychological symptom of FXS includes chronic anxiety in any form, social aversion, behaviors obsessive-compulsive, aggression, agitation, self-destructive behavior or any combination thereof. |